LegalView Launches Byetta Information Portal to Provide Patients with the Details of Diabetes Drug Dangers

Share Article

LegalView has launched a new information portal on the type 2 diabetes drug Byetta, which has been allegedly linked to the deaths of patients for inducing life-threatening pancreas conditions. The FDA will also be increasing the drug's labeling after several patients were hospitalized because of inflamed pancreases developed while taking the drug.

LegalView, the best resource for everything and anything legal on the Web, launched its new Byetta information portal to offer details of potential Byetta side effects of taking the type 2 diabetes drug. In August, the U.S. Food and Drug Administration (FDA) announced it would increase warning labeling regarding Byetta after several patients were hospitalized and two patients died because of life-threatening pancreas issues, allegedly linked to Byetta. Patients who are taking Byetta should consult with their doctor and may want to consider speaking with an experienced pharmaceutical attorney who can provide insight into a potential Byetta class action lawsuit.

Byetta (exanatide), which treats type 2 diabetes, was approved for market in August 2005 from makers Amilyn Pharmaceuticals and Eli Lilly and Company. The drug is an injectable medicine that controls glucose (blood sugar) levels among adults with diabetes. The FDA is working with the drug's manufacturers to increase the warning labeling on the drug because of signs of hemorrhagic pancreatitis, which is inflammation of the pancreas that also causes bleeding, and necrotizing pancreatitis in which the pancreas becomes inflamed and essentially destroys itself internally. According to news reports, the FDA had nearly 30 reports of acute pancreatitis recently, from as early as October 2007. Those wishing to know more about the possible Byetta risks can contact a pharmaceutical law firm that can potentially offer an experienced Byetta lawyer .

In addition to the details of the Byetta risks, LegalView also offers readers several other pharmaceutical information portals on topics such as Avandia, Ketek and the Zimmer Durom cups.

Avandia, which is similar to Byetta, is a type 2 diabetes drug that has been under a wave of controversy after several medical studies linked the drug to heart failure and early onset osteoporosis among patients. The drug continues to remain on the market, even though the FDA acknowledged the serious potential risks of heart failure among Avandia patients. To learn more about the Avandia side effects, it is advised to speak with a medical professional.

The Ketek controversy occurred after approximately 18 deaths and 100 cases of liver damage reportedly occurred among patients taking the antibiotic. Ketek treats bacterial infections and upper respiratory conditions and has been available in the United States since 2004. The FDA has not issued a Ketek recall but is aware of the potential increase of liver disease and liver damage among Ketek patients and is currently investigating the drug.

The Durom cup, from Zimmer Holdings, is an artificial hip socket used in hip replacement surgeries. However, reports began flooding in from physicians across the country that the hip socket was failing in many of the 12,000 patients who have received the hip socket. To learn more about the Zimmer Durom cup contact a knowledgeable medical professional as well as a pharmaceutical attorney who can assist in learning about a potential Zimmer Durom cup lawsuit is developed.

About LegalView: is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Katie Kelley

Alan Haburchak
Visit website